Fulcrum Therapeutics, Inc.

NASDAQ:FULC

Biotechnology

Healthcare
$3.72 +1.71%

+$0.06 today

Market cap
$284.14M
Beta
2.92
P/E (TTM)
-3.6
EPS (TTM)
-$1.00
52W Low $2.83High $15.74

Volume 0.63M

Average 1.78M

FULC Selling, General & Admin

Overhead costs of running the business, including sales, marketing, management, and administrative staff.

Fulcrum Therapeutics, Inc.NASDAQ: FULC

Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026

Selling, general & admin growth accelerates

Q1 FY2026 selling, general & admin of $8.1M rose 15.8% year over year, ahead of the -10.8% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 11.3% from the prior quarter. Over 3 fiscal years it compounded at -11.7% a year.

Context

  • Selling, general & admin increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether selling, general & admin reaches the consensus estimate from 5 analysts of $1.53M (-94.7%) for the fiscal year ending Dec 2026, a slowdown from the -21.4% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$8.1M+11.3% QoQ
Last fiscal yearDec 2025
$28.67M-21.4% YoY
LTMMar 2026
$29.77M-10.8% YoY
Selling, General & Admin past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+15.8%-100.0%-115.8 pp
1 year-21.4%-94.7%-73.3 pp
3-year CAGR-11.7%+110.3%+122.1 pp
5-year CAGR+20.7%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Selling, General & Admin history

USD · from the income statement

Latest · FY2025
28.67M USD
Year-over-year change
-21.4%
4-year CAGR
-1.6%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Selling, General & Admin vs competitors

How FULC compares with its peers on the latest reported figures

  • FULC's LTM Mar 2026 selling, general & admin of $29.77M is the 6th highest of the 10 companies compared; the peer median is $33.4M.
  • Its year-over-year change of -10.8% is the 7th highest of 10, against a peer median of +3.6%.
  • Over three fiscal years its annual growth of -11.7% compares with a peer median of +13.1%.
FULC Competitors Peer median
Selling, General & Admin for FULC and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ADCTADC Therapeutics S.A.LTM Mar 2026$82.03M +32.5%—103.6%
BCYCBicycle Therapeutics plcLTM Mar 2026$76.67M +0.6%+17.4%120.8%
NMRANeumora Therapeutics, Inc. Common StockLTM Mar 2026$55.57M -17.1%+24.5%—
LXRXLexicon Pharmaceuticals, Inc.LTM Mar 2026$34.94M -61.3%—50.2%
OMEROmeros CorporationLTM Mar 2026$33.4M -31.3%-6.4%337.6%
FULCFulcrum Therapeutics, Inc.LTM Mar 2026$29.77M -10.8%-11.7%—
OCGNOcugen, Inc.LTM Mar 2026$29.24M +9.4%-8.0%654.9%
NGNENeurogene Inc.LTM Mar 2026$27.57M +8.0%+40.7%—
LCTXLineage Cell Therapeutics, Inc.LTM Mar 2026$18.69M +3.6%-6.4%126.4%
CMPXCompass Therapeutics, Inc.LTM Mar 2026$18.51M +10.2%+13.1%—
Peer median (excluding FULC) $33.4M+3.6%+13.1%123.6%

Competitors are the stored peer set for FULC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue19.16M6.34M2.81M80M0
Cost of Revenue69.7M76.78M71.8M63.39M1.39M
Gross Profit(50.54M)(70.44M)(69M)16.61M(1.39M)
Gross Margin-263.7%-1110.7%-2459.8%20.8%—
Research & Development69.7M76.78M71.8M63.39M56.1M
Selling, General & Admin30.52M41.69M41.67M36.45M28.67M
Operating Expenses30.52M42.12M41.67M38.51M83.38M
Depreciation & Amortization2.52M2.41M2.17M1.59M1.39M
EBITDA(78.33M)(109.72M)(95.16M)(18.24M)(73.49M)
EBITDA Margin-408.8%-1730.1%-3392.6%-22.8%—
Operating Income(81.05M)(112.56M)(110.66M)(21.9M)(84.77M)
Operating Margin-423.0%-1774.9%-3945.2%-27.4%—
Interest Income207K0000
Interest Expense00000
Other Income / Expenses207K2.69M13.33M12.17M9.89M
Income Before Tax(80.85M)(109.87M)(97.34M)(9.73M)(74.88M)
Pre-Tax Margin-421.9%-1732.4%-3470.1%-12.2%—
Income Tax Expense00000
Net Income(80.85M)(109.87M)(97.34M)(9.73M)(74.88M)
Net Margin-421.9%-1732.4%-3470.1%-12.2%—
EPS (Basic)(2.22)(2.35)(1.59)(0.16)(1.18)
EPS (Diluted)(2.22)(2.35)(1.59)(0.16)(1.18)
Weighted Avg Shares35.36M44.99M61.31M61.98M63.36M
Weighted Avg Shares (Diluted)35.36M44.99M61.31M61.98M63.36M

Fulcrum Therapeutics, Inc.

NASDAQ:FULC

Intrinsic Alpha fair value

Locked

Current Price

$3.72

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.